The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

an inhalable treatment for treatment-resistant depression (TRD), demonstrating a significant placebo-adjusted reduction in depression scores as measured by the MADRS scale on Day 8. The trial ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

Although antidepressants are still commonly used to treat depression, one-third of individuals are unresponsive to medication, resulting in what is known as treatment-resistant depression (TRD). Hence ...

Researchers at CU Anschutz are studying the effect of psychedelic mushrooms on patients with treatment-resistant depression.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

A trial for psilocybin therapy to treat depression is being opened to Vancouver Island applicants. Psilocybin is a ...

A trial for psilocybin therapy to treat depression is being opened to applicants in the Nanaimo area. Psilocybin is a ...

DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...